<DOC>
	<DOCNO>NCT01560117</DOCNO>
	<brief_summary>Immunotherapy monoclonal anti-CD20 antibody rituximab become standard care patient follicular lymphoma . However , still open question regard dose schedule rituximab , optimal type chemotherapeutic combination partner induction well best interval length rituximab maintenance treatment . Fludarabine-mitoxantrone combination show strong debulking activity initial therapy follow rituximab maintenance . While rituximab maintenance standard dose 375 mg/m2 prolongs clinical remission , administration schedule still vary : Three-monthly infusion 2 year two-monthly infusion one 2 year frequently use . A pharmacokinetic data rituximab report induction treatment . These study propose presumptive `` active '' level 25.000 ng/ml anti-lymphoma treatment . However , limited information regard maintenance treatment patient remission remain tumor load . The aim trial investigate effect treatment oral Fludarabine , Mitoxantrone und Rituximab Rituximab maintenance depth remission measure BCL2/IgH PCR .</brief_summary>
	<brief_title>Combination Oral Fludarabine , Mitoxantrone Und Rituximab Induction Therapy Rituximab Maintenance Therapy Follicular B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>positive BCL2/IgH rearrangement peripheral blood ( PB ) and/or bone marrow ( BM ) clinical stage III IV , require treatment one follow criterion : symptom related disease , hemoglobin le 12 g/dL , platelets less 100 G/L , progressive disease , bulky tumor 10 cm pretreatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AGMT</keyword>
	<keyword>NHL</keyword>
</DOC>